{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:48:33Z","timestamp":1790524113277,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2010-0029220"],"award-info":[{"award-number":["2010-0029220"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2013M3A9D3045879"],"award-info":[{"award-number":["2013M3A9D3045879"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health, USA","doi-asserted-by":"crossref","award":["CA177932"],"award-info":[{"award-number":["CA177932"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jconrel.2015.10.009","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T05:38:06Z","timestamp":1445837886000},"page":"181-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Polymeric oncolytic adenovirus for cancer gene therapy"],"prefix":"10.1016","volume":"219","author":[{"given":"Joung-Woo","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.10.009_bb0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bpa.2013.10.010","article-title":"The global burden of cancer","volume":"27","author":"Popat","year":"2013","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/B978-0-12-398342-8.00004-5","article-title":"Chapter four\u2014design of improved oncolytic adenoviruses","volume":"115","author":"Alemany","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.molmed.2012.07.007","article-title":"Recombinant viral vaccines for cancer","volume":"18","author":"Cawood","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0020","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.addr.2006.05.005","article-title":"Recombinant viral vectors: cancer vaccines","volume":"58","author":"Harrop","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000808","article-title":"A capsid-encoded PPxY-motif facilitates adenovirus entry","volume":"6","author":"Wodrich","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.addr.2009.03.013","article-title":"Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis","volume":"61","author":"Dorer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0304-3835(02)00017-4","article-title":"Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells","volume":"180","author":"Kim","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0045","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/104303403769211637","article-title":"Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner","volume":"14","author":"Kim","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0050","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-10-0664","article-title":"A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas","volume":"16","author":"Kwon","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0055","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"Cattaneo","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/hum.1995.6.2-155","article-title":"Safety evaluation of Ad5CMV-p53 in vitro and in vivo","volume":"6","author":"Zhang","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0065","first-page":"107","article-title":"Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells","volume":"1","author":"Shewach","year":"1994","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0070","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1089\/hum.1995.6.8-1055","article-title":"In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine","volume":"6","author":"Hirschowitz","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0075","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.gt.3301725","article-title":"Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices","volume":"9","author":"Sanz","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.cgt.7700769","article-title":"ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis","volume":"12","author":"Yun","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0085","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djj397","article-title":"Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy","volume":"98","author":"Kim","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2009.142","article-title":"Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy","volume":"17","author":"Choi","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coviro.2015.03.009","article-title":"Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints","volume":"13","author":"Jiang","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0100","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.gt.3302759","article-title":"Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect","volume":"13","author":"Choi","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0105","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1158\/1078-0432.CCR-06-0935","article-title":"Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model","volume":"12","author":"Lee","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0110","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrc1627","article-title":"Tumour vascular targeting","volume":"5","author":"Neri","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/gt.2008.3","article-title":"Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition","volume":"15","author":"Yoo","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-07-1510","article-title":"Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus","volume":"14","author":"Qiao","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/mt.2008.288","article-title":"MicroRNAs and the regulation of vector tropism","volume":"17","author":"Kelly","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.mt.6300023","article-title":"VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth","volume":"15","author":"Yoo","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0135","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1586\/14760584.2013.836912","article-title":"Oncolytic vaccines","volume":"12","author":"Elsedawy","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2014.00188","article-title":"Oncolytic viruses as anticancer vaccines","volume":"4","author":"Woller","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0145","first-page":"7853","article-title":"Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model","volume":"63","author":"Satoh","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037812","article-title":"Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation","volume":"7","author":"Alberti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/cgt.2010.4","article-title":"Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study","volume":"17","author":"Garcia-Castro","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0160","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","article-title":"Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model","volume":"15","author":"Mader","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0165","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1089\/10430340050057549","article-title":"Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed\/refractory neuroblastoma using an adenoviral vector","volume":"11","author":"Brenner","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0170","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/gt.2009.29","article-title":"Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity","volume":"16","author":"Ilett","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1078-0432.CCR-08-1688","article-title":"Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2","volume":"15","author":"Kottke","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0180","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/jnci\/djm229","article-title":"Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy","volume":"99","author":"Kurozumi","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2014.05.003","article-title":"Association of oncolytic adenoviruses with chemotherapies: an overview and future directions","volume":"90","author":"Bressy","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2014.00191","article-title":"Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses","volume":"4","author":"Forbes","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0195","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(05)71407-0","article-title":"Oncolytic viral anti-cancer therapy: a magic bullet?","volume":"357","author":"Bradbury","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0200","article-title":"Trial watch: oncolytic viruses for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0205","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4161\/onci.20172","article-title":"Oncolytic adenoviruses: a potent form of tumor immunovirotherapy","volume":"1","author":"Cerullo","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/cgt.2011.7","article-title":"Clinical development directions in oncolytic viral therapy","volume":"18","author":"Eager","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0215","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0220","first-page":"4200","article-title":"The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0225","article-title":"Trial Watch: oncolytic viruses for cancer therapy","volume":"3","author":"Pol","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0230","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0235","author":"Bramante"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0240","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1089\/hum.2007.074","article-title":"Long-term outcome of phase I\/II clinical trial of Ad-OC-TK\/VAL gene therapy for hormone-refractory metastatic prostate cancer","volume":"18","author":"Shirakawa","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0245","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1442-2042.2006.01418.x","article-title":"Progress report on phase I\/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: initial experience at Kobe University","volume":"13","author":"Hinata","year":"2006","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0250","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0255","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0260","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/156652309789753356","article-title":"Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas","volume":"9","author":"Jiang","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0265","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/hum.1998.9.9-1323","article-title":"A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy","volume":"9","author":"Freytag","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0270","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0275","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0280","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0285","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2119\/2006-00115.Zhang","article-title":"Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library","volume":"13","author":"Zhang","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1517\/14712598.6.8.823","article-title":"INGN 201 (Advexin): adenoviral p53 gene therapy for cancer","volume":"6","author":"Gabrilovich","year":"2006","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrmicro3140","article-title":"New viruses for cancer therapy: meeting clinical needs","volume":"12","author":"Miest","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0300","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0305","doi-asserted-by":"crossref","first-page":"805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv Virol"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0310","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.4103\/2141-9248.141953","article-title":"Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol","volume":"4","author":"Shilpa","year":"2014","journal-title":"Ann. Med. Health Sci. Res"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0315","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0320","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0325","first-page":"693","article-title":"Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies","volume":"9","author":"Makower","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0330","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1089\/10430349950018364","article-title":"Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo","volume":"10","author":"Muruve","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0335","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/mthe.2001.0330","article-title":"Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors","volume":"3","author":"Schnell","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0340","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/mthe.2001.0329","article-title":"Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages","volume":"3","author":"Zhang","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0345","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/JVI.69.4.2004-2015.1995","article-title":"Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses","volume":"69","author":"Yang","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0350","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1089\/hum.1998.9.14-2121","article-title":"Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma","volume":"9","author":"Molnar-Kimber","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0355","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0360","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jviromet.2007.08.009","article-title":"A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells","volume":"147","author":"Smith","year":"2008","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0365","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.gt.3302875","article-title":"Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector","volume":"14","author":"Myhre","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0370","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"O'Riordan","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0375","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1128\/JVI.75.10.4792-4801.2001","article-title":"\u201cStealth\u201d adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung","volume":"75","author":"Croyle","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0380","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1016\/j.biomaterials.2011.08.066","article-title":"Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0385","first-page":"249","article-title":"The uses and properties of PEG-linked proteins","volume":"9","author":"Delgado","year":"1992","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0390","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003088-200645100-00002","article-title":"Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs","volume":"45","author":"Parveen","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0395","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/138920106777950852","article-title":"Novel delivery technologies for protein and peptide therapeutics","volume":"7","author":"Kumar","year":"2006","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0400","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0405","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.mt.6300306","article-title":"Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies","volume":"16","author":"Wortmann","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0410","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/hum.2009.028","article-title":"Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus","volume":"20","author":"Doronin","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0415","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0420","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","article-title":"Endosomal escape pathways for delivery of biologicals","volume":"151","author":"Varkouhi","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0425","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0430","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2008.06.024","article-title":"Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction","volume":"132","author":"Yockman","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0435","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1023\/A:1015166806366","article-title":"Novel water insoluble lipoparticulates for gene delivery","volume":"19","author":"Furgeson","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0440","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0168-3659(01)00547-8","article-title":"Biodegradable poly(ethylenimine) for plasmid DNA delivery","volume":"80","author":"Ahn","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0445","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.colsurfb.2014.07.007","article-title":"Low molecular weight PEIs modified by hydrazone-based crosslinker and betaine as improved gene carriers","volume":"122","author":"Fang","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0450","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jgm.696","article-title":"Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis","volume":"7","author":"Akinc","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0455","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/acs.biomac.5b00538","article-title":"Oncolytic adenovirus coated with multidegradable bioreducible core-cross-linked polyethylenimine for cancer gene therapy","volume":"16","author":"Choi","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0460","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1016\/j.biomaterials.2014.03.060","article-title":"Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression","volume":"35","author":"Lee","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0465","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.252.5010.1231-b","article-title":"Dendrimer research","volume":"252","author":"Tomalia","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0470","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/bc00023a012","article-title":"Polyamidoamine cascade polymers mediate efficient transfection of cells in culture","volume":"4","author":"Haensler","year":"1993","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0475","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1073\/pnas.93.10.4897","article-title":"Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers","volume":"93","author":"Kukowska-Latallo","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0480","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2967\/jnumed.112.115493","article-title":"Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene","volume":"54","author":"Grunwald","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0485","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1016\/j.biomaterials.2013.03.004","article-title":"Therapeutic efficacy of a systemically delivered oncolytic adenovirus\u2013biodegradable polymer complex","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0490","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/bm501116x","article-title":"Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model","volume":"16","author":"Jung","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0495","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0500","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.29528","article-title":"Barriers to drug delivery in solid tumors","volume":"2","author":"Sriraman","year":"2014","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0505","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1359-6446(02)02243-2","article-title":"Targeting tumors with non-viral gene delivery systems","volume":"7","author":"Ogris","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0510","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0515","first-page":"51","article-title":"Antibody conjugation methods for active targeting of liposomes","volume":"25","author":"Ansell","year":"2000","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0520","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3109\/1061186X.2014.910792","article-title":"Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours","volume":"22","author":"Manjappa","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0525","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7150\/thno.10257","article-title":"Aptamers: active targeting ligands for cancer diagnosis and therapy","volume":"5","author":"Wu","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0530","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/pharmaceutics5020329","article-title":"Polysaccharide-based micelles for drug delivery","volume":"5","author":"Zhang","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/thno.3463","article-title":"Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy","volume":"2","author":"Yu","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0540","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1016\/j.biomaterials.2011.03.084","article-title":"Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0545","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1016\/j.biomaterials.2013.12.086","article-title":"Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors","volume":"35","author":"Ge","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0550","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/gt.2014.18","article-title":"Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer","volume":"21","author":"Kim","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0555","first-page":"852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0560","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/era.10.226","article-title":"HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies","volume":"11","author":"Gajria","year":"2011","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0565","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/bjc.2013.831","article-title":"Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM\/2006-14 trial","volume":"110","author":"Alba","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0570","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.biomaterials.2010.10.031","article-title":"Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0575","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.addr.2004.01.005","article-title":"Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor","volume":"56","author":"Zhao","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0580","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2013.03.030","article-title":"Therapeutic targeting of chitosan\u2013PEG\u2013folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy","volume":"169","author":"Kwon","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0585","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2010.06.027","article-title":"Ionically crosslinked Ad\/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy","volume":"148","author":"Park","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0590","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0595","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2217\/nnm.12.160","article-title":"EGF receptor-targeted nanocarriers for enhanced cancer treatment","volume":"7","author":"Master","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0600","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.58","article-title":"EGFR-targeted adenovirus dendrimer coating for improved systemic delivery of the theranostic NIS gene","volume":"2","author":"Grunwald","year":"2013","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0605","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2014.11.021","article-title":"Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus","volume":"41","author":"Moon","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0610","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2015.01.005","article-title":"pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis","volume":"205","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.10.009_bb0615","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/fon.11.13","article-title":"Influence of the tumor microenvironment on angiogenesis","volume":"7","author":"Payne","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0620","first-page":"4373","article-title":"Acid pH in tumors and its potential for therapeutic exploitation","volume":"49","author":"Tannock","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.10.009_bb0625","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1476-5381.2009.00288.x","article-title":"Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers","volume":"157","author":"Midoux","year":"2009","journal-title":"Br. J. Pharmacol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915301784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915301784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:12:25Z","timestamp":1748664745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915301784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":125,"alternative-id":["S0168365915301784"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.009","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymeric oncolytic adenovirus for cancer gene therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}